BRAF and neoplasm: Based on the need for rationally improving the activity of clinically available agents, in the present study we used various molecularly characterized human melanoma cells, including cell lines with intrinsic resistance to the BRAF inhibitor vemurafenib, and ret transgenic mice to suppress tumor cell survival signals employing the pan-HDAC-inhibitor SAHA in combination with TMZ.